HAYWARD Calif., Oct. 12 /PRNewswire/ -- Multispan Inc., an emerging San Francisco Bay Area biotechnology company, announced today a license agreement with Medarex, Inc., a leader in the discovery and development of therapeutic fully human monoclonal antibodies. Multispan will provide HEx(TM) G-protein Coupled Receptor (GPCR) over-expressing cell lines for use as whole cell immunogens by Medarex. Specific targets and financial details were not disclosed.
"We are excited to be working with Medarex," said Helena Mancebo, Multispan's founder and Chief Executive Officer. "We believe GPCRs represent a largely unexplored area for therapeutic antibody development and have confidence that the combination of our high expression cell lines and Medarex's proven, fully-human, antibody generation capability could lead to new antibody based treatments for important diseases."
Multispan Inc. is a San Francisco Bay Area-based biotechnology company focused exclusively on GPCRs, a most important protein class of therapeutic targets. Privately held, and founded in 2004, Multispan has created the industry's largest collection of human GPCR clones and has engineered a large collection of GPCR-expressing cell lines, including the proprietary HEx(TM) series of High Expression cell lines.
For further information, please visit the Multispan website (www.multispaninc.com) or contact Helena Mancebo (firstname.lastname@example.org).
CONTACT: Helena Mancebo of Multispan Inc., +1-510-887-0817, ext. 101, email@example.com